The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus

被引：0
|
作者：
Jason Gordon
Phil McEwan
Michael Hurst
Jorge Puelles
机构：
[1] Health Economics and Outcomes Research Ltd,School of Medicine
[2] University of Nottingham,Department of Public Health
[3] University of Adelaide,Swansea Centre for Health Economics
[4] Swansea University,undefined
[5] Global Outcomes Research,undefined
[6] Takeda Development Centre Europe Ltd,undefined
来源：
Diabetes Therapy | 2016年 / 7卷
关键词：
Alogliptin; Cost-effectiveness analysis; Glycemic durability; Sulfonylurea; Second-line therapy; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：825 / 845
页数：20
相关论文
共 50 条
  • [1] The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
    Gordon, Jason
    McEwan, Phil
    Hurst, Michael
    Puelles, Jorge
    [J]. DIABETES THERAPY, 2016, 7 (04) : 825 - 845
  • [2] The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    [J]. DIABETIC MEDICINE, 2015, 32 (07) : 890 - 898
  • [3] COST-EFFECTIVENESS ANALYSIS OF LINAGLIPTIN VERSUS SULFONYLUREA AS ADD-ON TREATMENT TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN INDONESIA
    Endarti, D.
    Kristin, E.
    Pratiwi, W. R.
    Pinzon, R. T.
    Nugrahaningsih, D. A.
    Yasmina, A.
    Febrinasari, R. P.
    [J]. VALUE IN HEALTH, 2018, 21 : S39 - S39
  • [4] DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COLOMBIA
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Aschner, P.
    Garrido Lecca, S.
    Aiello, E.
    Jimenez, C.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A247 - A247
  • [5] IMPROVED GLYCEMIC CONTROL WITH INSULIN GLARGINE VERSUS PIOGLITAZONE AS ADD-ON THERAPY TO SULFONYLUREA OR METFORMIN IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS
    Meneghini, Luigi F.
    Traylor, Louise
    Schwartz, Sherwyn L.
    [J]. ENDOCRINE PRACTICE, 2010, 16 (04) : 588 - 599
  • [6] DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COSTA RICA
    Elgart, J. F.
    Gonzalez, L.
    Prestes, M.
    Vinocour, M.
    Solorzano, J.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A202 - A202
  • [7] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Nicholas Tentolouris
    Georgia Kourlaba
    Nikos Maniadakis
    [J]. Clinical Drug Investigation, 2016, 36 : 649 - 659
  • [8] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Tentolouris, Nicholas
    Kourlaba, Georgia
    Maniadakis, Nikos
    [J]. CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 649 - 659
  • [9] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
    Pititto, L.
    Neslusan, C.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    Asano, E.
    Puig, A.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
  • [10] COST-EFFECTIVENESS OF ADD-ON THERAPIES TO METFORMIN: THE IMPACT OF MEDICATION ADHERENCE FOR TYPE 2 DIABETES MELLITUS
    Ho, C. M.
    Yeh, T. H.
    Lai, Y. T.
    [J]. VALUE IN HEALTH, 2021, 24 : S80 - S80
12345